Government panel recommends Corbevax for emergency use in kids aged five to 11 years
Biological E's Corbevax is being used to inoculate children against COVID-19 in the age group of 12 to 14 years
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
SEC
Bharat Biotech awaits regulatory approvals to launch Covaxin for children
The SEC on COVID-19 examined the data and deliberated on the EUA application yesterday
DCGI expert committee allows clinical trials for third dose of Bharat Biotech’s Covaxin
The committee recommended that the firm may unblind the participants of age group of more than 45 years and offer to administer…
SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech
To reconvene on Jan 1, 2021
SEC asks Bharat Serums to revise phase I/II trial protocols for equine antiserum to treat COVID-19
The SEC has recommended grant of permission to conduct the clinical trial provided the company submits the revised clinical trial…
Bharat Biotech seeks EUA for Covaxin
No date has been fixed as on when the SEC will meet for assessing and evaluating the applications, as per sources
SEC asks Biocon to submit safety, mortality data for Itolizumab
The company claims that approximately 2000 COVID-19 patients used the drug under the emergency use authorisation
SEC asks CDSCO to submit adverse event report of death during Umifenovir trial
It should include analysis of the ethics committee, investigator and sponsor etc., for review
Glenmark set to get manufacturing and marketing approval for favipiravir
Sources inform that SEC has recommended the grant of permission, along with some recommendations, the company plans to launch its…